Why Gilead Sciences Inc Is A Buy? Acquirer’s Multiple Stock Screener Analysis
Thursday, December 14, 2023 · Johnny Hopkins
As part of our ongoing series here at The Acquirer’s Multiple, each week we focus on one of the stocks from our Stock Screeners, and why it’s a ‘buy’ based on key fundamentals.
One of the cheapest stocks in our Stock Screeners is:
Gilead Sciences Inc (GILD)
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead’s acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead’s exposure to cell therapy and noncell therapy in oncology.
A quick look at the share price history (below) over the past twelve months shows that the price is down 11.23%. Here’s why the company is undervalued.
Key Stats
Market Cap: $98.54 Billion
Enterprise Value: $115.47 Billion
Operating Earnings
Operating Earnings: $9.52 Billion
Acquirer’s Multiple
Acquirer’s Multiple: 12.10
Free Cash Flow (TTM)
Free Cash Flow: $7.85 Billion
FCF/EV Yield %:
FCF/EV Yield: 7.97
Shareholder Yield %:
Shareholder Yield: 5.10
Other Indicators
Piotroski F Score: 8.00
Altman Z-Score (TTM): 2.704
ROA (5 Year Avge%): 15